Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125673163 | 12567316 | 3 | F | 20160617 | 20160718 | 20160720 | PER | US-ASTELLAS-2016US019685 | ASTELLAS | 0.00 | F | Y | 0.00000 | 20160720 | CN | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125673163 | 12567316 | 1 | PS | VESICARE | SOLIFENACIN SUCCINATE | 1 | Unknown | U | 21518 | 10 | MG | TABLET | |||||||
125673163 | 12567316 | 2 | SS | MYRBETRIQ | MIRABEGRON | 1 | Unknown | U | 0 | 25 | MG | TABLET | QD | ||||||
125673163 | 12567316 | 3 | SS | MYRBETRIQ | MIRABEGRON | 1 | Unknown | 50 MG (2 X 25 MG), ONCE DAILY | U | 0 | 50 | MG | TABLET | QD | |||||
125673163 | 12567316 | 4 | SS | MYRBETRIQ | MIRABEGRON | 1 | Unknown | 0 | 50 | MG | TABLET | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125673163 | 12567316 | 1 | Hypertonic bladder |
125673163 | 12567316 | 2 | Hypertonic bladder |
125673163 | 12567316 | 4 | Hypertonic bladder |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125673163 | 12567316 | Drug ineffective | |
125673163 | 12567316 | Urinary incontinence |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |